Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Value Line, Inc is a financial data & stock exchanges business based in the US. Value Line shares (VALU) are listed on the NASDAQ and all prices are listed in US Dollars. Value Line employs 161 staff and has a trailing 12-month revenue of around USD$41.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$19.9963 - USD$35.95 |
---|---|
50-day moving average | USD$30.5267 |
200-day moving average | USD$28.3622 |
Wall St. target price | N/A |
PE ratio | 16.0837 |
Dividend yield | USD$0.83 (2.81%) |
Earnings per share (TTM) | USD$1.864 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Value Line stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Value Line's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Value Line's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Value Line shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Value Line's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$9.6 million.
The EBITDA is a measure of a Value Line's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$41.1 million |
---|---|
Operating margin TTM | 21.51% |
Gross profit TTM | USD$35.4 million |
Return on assets TTM | 5.21% |
Return on equity TTM | 32.39% |
Profit margin | 43.6% |
Book value | $6.169 |
Market capitalisation | USD$287.5 million |
TTM: trailing 12 months
There are currently 11,279 Value Line shares held short by investors – that's known as Value Line's "short interest". This figure is 5.2% up from 10,726 last month.
There are a few different ways that this level of interest in shorting Value Line shares can be evaluated.
Value Line's "short interest ratio" (SIR) is the quantity of Value Line shares currently shorted divided by the average quantity of Value Line shares traded daily (recently around 7005.5900621118). Value Line's SIR currently stands at 1.61. In other words for every 100,000 Value Line shares traded daily on the market, roughly 1610 shares are currently held short.
However Value Line's short interest can also be evaluated against the total number of Value Line shares, or, against the total number of tradable Value Line shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Value Line's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Value Line shares in existence, roughly 0 shares are currently held short) or 0.0119% of the tradable shares (for every 100,000 tradable Value Line shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Value Line.
Find out more about how you can short Value Line stock.
Dividend payout ratio: 44.77% of net profits
Recently Value Line has paid out, on average, around 44.77% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.8% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Value Line shareholders could enjoy a 2.8% return on their shares, in the form of dividend payments. In Value Line's case, that would currently equate to about $0.83 per share.
While Value Line's payout ratio might seem fairly standard, it's worth remembering that Value Line may be investing much of the rest of its net profits in future growth.
Value Line's most recent dividend payout was on 11 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 January 2021 (the "ex-dividend date").
Over the last 12 months, Value Line's shares have ranged in value from as little as $19.9963 up to $35.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Value Line's is -0.0085. This would suggest that Value Line's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Value Line has bucked the trend.
Value Line, Inc., together with its subsidiaries, produces and sells investment periodicals and related publications primarily in the United States. Its investment periodicals and related publications cover a range of investments, including stocks, mutual funds, exchange traded funds (ETFs), and options. The company offers research services, such as The Value Line Investment Survey, The Value Line Investment Survey - Small and Mid-Cap, The Value Line 600, and The Value Line Fund Advisor Plus, which provide statistical and text coverage of various investment securities, with an emphasis placed on its proprietary research, analysis, and statistical ranks. It also provides niche newsletters comprising Value Line Select, Value Line Select: Dividend Income & Growth, Value Line Select: ETFs, and The Value Line Special Situations Service that offer information on a less comprehensive basis for securities that are of particular interest to subscribers; digital versions of its products through its Website, www.valueline.com, as well as The Value Line Research Center online platform; and investment analysis software, such as The Value Line Investment Analyzer, which includes data sorting and filtering tools. In addition, the company offers current and historical financial databases comprising DataFile, estimates and projections, and mutual funds through the Internet; and copyright products, which include unit investment trusts, variable annuities, managed accounts, and EFTs. Further, it places advertising on behalf of the company's publications; and provides subscription fulfillment and subscriber relation services. The company serves individual and professional investors, as well as institutions, including municipal and university libraries, and investment firms. Value Line, Inc. was founded in 1931 and is headquartered in New York, New York. Value Line, Inc. is a subsidiary of Arnold Bernhard & Co, Inc.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.